Moderna (NASDAQ:MRNA) Price Target Lowered to $50.00 at Evercore ISI

Moderna (NASDAQ:MRNA - Free Report) had its target price reduced by Evercore ISI from $60.00 to $50.00 in a research report report published on Monday,Benzinga reports. They currently have an in-line rating on the stock.

A number of other equities analysts also recently weighed in on the stock. Argus downgraded shares of Moderna from a "buy" rating to a "hold" rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. reduced their target price on Moderna from $59.00 to $45.00 and set an "underweight" rating on the stock in a report on Tuesday, November 26th. Morgan Stanley dropped their price target on Moderna from $70.00 to $38.00 and set an "equal weight" rating for the company in a research note on Wednesday, January 15th. Hsbc Global Res raised Moderna from a "hold" rating to a "strong-buy" rating in a research note on Monday, November 18th. Finally, Sanford C. Bernstein began coverage on Moderna in a report on Thursday, October 17th. They set a "market perform" rating and a $55.00 target price for the company. Four equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $71.89.

Remove Ads

Moderna Trading Up 0.5 %

Shares of MRNA stock traded up $0.23 during mid-day trading on Monday, hitting $41.64. 12,144,970 shares of the company's stock were exchanged, compared to its average volume of 12,827,622. The stock has a market cap of $16.02 billion, a price-to-earnings ratio of -7.15 and a beta of 1.60. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. Moderna has a fifty-two week low of $31.94 and a fifty-two week high of $170.47. The stock has a 50-day simple moving average of $40.60 and a two-hundred day simple moving average of $63.29.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. The firm's quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the company earned ($1.39) EPS. Equities analysts expect that Moderna will post -9.27 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the business's stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares of the company's stock, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders sold 2,664 shares of company stock worth $115,210. Insiders own 15.70% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in MRNA. Axiom Advisory LLC raised its stake in Moderna by 1.6% during the third quarter. Axiom Advisory LLC now owns 12,672 shares of the company's stock worth $847,000 after acquiring an additional 198 shares during the period. Arkadios Wealth Advisors raised its position in shares of Moderna by 2.2% during the 3rd quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company's stock worth $764,000 after purchasing an additional 243 shares during the period. Knuff & Co LLC lifted its holdings in shares of Moderna by 5.4% in the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company's stock worth $316,000 after purchasing an additional 244 shares during the last quarter. Stephens Inc. AR boosted its position in Moderna by 7.9% during the 3rd quarter. Stephens Inc. AR now owns 3,334 shares of the company's stock valued at $223,000 after purchasing an additional 245 shares during the period. Finally, Mather Group LLC. grew its stake in Moderna by 25.7% during the 3rd quarter. Mather Group LLC. now owns 1,281 shares of the company's stock worth $86,000 after buying an additional 262 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.